Leung RC, Ip JD, Chen LL, Chan WM, To KK. Global emergence of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses with I223V and S247N mutations: implications for antiviral resistance monitoring. Lancet Microbe. 2024 Mar 14:S2666-5247(24)00037-5
Neuraminidase inhibitors (NAIs), such as oseltamivir and zanamivir, serve as the primary treatment for influenza virus infection. NAI-resistant influenza A(H1N1) strains were widespread during the 2008–09 influenza season, especially in Japan, where 100% of the strains were resistant to oseltamivir. However, after the NAI-susceptible 2009 pandemic subtype (A[H1N1]pdm09) replaced the previous seasonal A(H1N1) subtype in 2009, the incidence of A(H1N1)pdm09 with reduced inhibition (10-fold to 100-fold) or highly reduced inhibition (>100-fold) was only approximately 1% in the 2019–20 influenza season.
See Also:
Latest articles in those days:
- Oxymatrine Modulation of TLR3 Signaling: A Dual-Action Mechanism for H9N2 Avian Influenza Virus Defense and Immune Regulation 8 hours ago
- Advax-SM?-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines 8 hours ago
- Triggering Degradation of Host Cellular Proteins for Robust Propagation of Influenza Viruses 8 hours ago
- Influenza Virus Genomic Surveillance, Arizona, USA, 2023–2024 8 hours ago
- Detection and Characterization of Influenza A Virus Endemic Circulation in Suckling and Nursery Pigs Originating from Vaccinated Farms in the Same Production System 8 hours ago
[Go Top] [Close Window]